Important: Keep the FDA Informed!

If you are having trouble with ANY of your medications:

Including problems with certain batches, please submit a report with the FDA;
http://www.fda.gov/medwatch/how.htm

King Pharmaceuticals, announcement of discontinuance of the manufacture of FLORINEF Acetate (Fludrocortisone Acetate Tablets, USP)

Decision based upon many factors, including understanding of current medical therapy and general availability of generic alternatives.
http://www.fda.gov/cder/drug/shortages/florinef.pdf
If you have any issues with this news, please make them known to the FDA (form is available at the FDA website http://www.fda.gov/medwatch/how.htm)

U.S. Food and Drug Administration Enforcement Report -
Recalls and Field Corrections: Drugs -- Class III

Check important recall information on Greenstone brand cabergoline and Dostinex tablets:

http://www.fda.gov/bbs/topics/enforce/2006/ENF00954.html

TOUCH BRIEFINGS: US ENDOCRINE DISEASE

Recent articles published by Touch Briefings:

Robert Costello—The Prophet of Pituitary Adenomas - Dec 2007 a report by Edward R Laws, MD, PhD, FACS and Robert Knutzen, MBA Foreword: A report by Robert Knutzen - Jan 2007 The Problem of the Aggressive Pituitary Tumor - Jan 2007 by Ian E McCutcheon, MD, FRCS(C) Professor, Department of Neurosurgery, The University of Texas M D Anderson Cancer Center The Difficulty of Pituitary Disorders - by Robert Knutzen and Linda Rio, MFT.  Click on 'Pituitary Disorders' to receive entire article. US ENDOCRINE REVIEW 2006 – JUNE 2006 - Entire Contents Erectile Dysfunction - Barometer of a Man’s Health - June 2006 by Steven Lamm, MD, Clinical Assistant Professor of Medicine, New York University School of MedicineClick on 'Erectile Dysfunction' US ENDOCRINE REVIEW 2005 - SEPTEMBER 2005 - Entire Contents Dispelling the Myths about Rarely Diagnosed Pituitary Disorders  by Robert Knutzen, MBA and Shereen Ezzat, MD Advisory Panel; US Endocrine Review - September 2005

Endocrine News June 2006 Article:
TESTOSTERONE THERAPY
FOR ANDROGEN DEFICIENT MEN
New Clinical Guideline from the Endocrine Society 

by Cathy Kristiansen, Editor

Prescribing testosterone therapy for male patients can be a controversial issue that leaves many physicians unclear if they are indeed giving optimal treatment and whether they are treating the right patients. To help clarify best practices in this field and provide guidance for the evaluation and treatment of male androgen deficiency,

The Endocrine Society has developed a guideline, Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes, which was recently published in The Journal of Clinical Endocrinology & Metabolism.

European Journal of Neuro-Endocrinology, Jan 2006
THE COST OF MEDICAL CARE FOR THE ACROMEGALIC PATIENT

by  Robert Knutzen, CEO PNA and Shereen Ezzat, M.D.

The subject of health care costs for patients with acromegaly is a difficult puzzle to solve. This is mostly because the disease has no clear limits with many permutations related to its complications. Thus, we feel obligated to emphasize at the outset that patients with acromegaly do not simply suffer from a tumorous disorder. They sustain a disorder characterized by insidious, seemingly “unrelated” symptoms and complaints, overlaid with severe hidden complications before the true diagnosis is established. Up until now, there has been no consensus on a standardized scientific approach to calculate the economic burden of the disease and all of its complications. The Cost of Medical Care for the Acromegalic Patient - read article

Cushing's Disease One of the Hardest to Diagnose

Doctors rarely see condition and end up treating secondary disease instead of cause

NEW YORK – Cushing's disease can be "one of the hardest diagnoses in medicine to make," says Dr. Daniel Kelly, associate professor of neurosurgery at UCLA Medical Centre, who brought one of his patients here to prove it. More...

NIH to Set Brain Tumor Research Priorities

In Current Edition Of Viewpoint From Veritas Medicine

Recently the National Cancer Institute (NCI) and the National Institute of Neurological Diseases and Stroke (NINDS) combined efforts to convene a Brain Tumor Progress Review Group (PRG), based on previous PRGs organized to provide overviews of breast and prostate cancer research. The goal of the Brain Tumor PRG (BT-PRG) was to identify scientific direction and funding priorities for brain tumor research. More...